



**Pharmacy Updates  
July-August 2018**

CenCal Health has made several changes to our Formulary based on clinical review, provider interest, cost and utilization analysis. All of the changes represent development and growth of our current Formulary thus giving more choices to the prescribing physician. The changes are represented in summary on the chart below.

Drug	Class	Formulary Status	Restrictions / Limits	Implementation Date
<b>Formulary Additions</b>				
ZenPep 30-10-14K, 15-47-63K	UPPER GASTROINTESTINAL DISORDERS-DIGESTIVE	Formulary		7/1/2018
Arnuity Ellipta 50mcg Inhaler	ASTHMA AND COPD	Formulary		8/1/2018
Patanol 0.1% Eye Drops	EYE ANTIHISTAMINES	Formulary		8/1/2018
Proctozone-HC 2.5% Cream	TOPICAL ANTI-INFLAMMATORY STERIODAL	Formulary		8/1/2018
<b>Formulary Changes</b>				
Invokana	DIABETES	Non-Formulary	Restriction: Non-Formulary, "Steglatro or Jardiance preferred agents"	8/1/2018
Farxiga	DIABETES	Non-Formulary	Restriction: Non-Formulary, "Steglatro or Jardiance preferred agents"	8/1/2018
Invokamet	DIABETES	Non-Formulary	Restriction: Non-Formulary, "Segluromet or Synjardy preferred agents"	8/1/2018
Invokamet XR	DIABETES	Non-Formulary	Restriction: Non-Formulary, "Segluromet or Synjardy preferred agents"	8/1/2018
Xigduo XR	DIABETES	Non-Formulary	Restriction: Non-Formulary, "Segluromet or Synjardy preferred agents"	8/1/2018